Osimertinib, a third-generation, irreversible EGFR–TKI, at either 25 mg/kg daily or 12.5 mg/kg daily exhibited minimal anti-tumor activity, with TGI of 24% and 4%, respectively. Here, EGFR is linked to neoplasm.